Literature DB >> 1808642

Pulse cyclophosphamide for severe neuropsychiatric lupus.

D T Boumpas1, H Yamada, N J Patronas, D Scott, J H Klippel, J E Balow.   

Abstract

We studied the effect of parenteral pulse cyclophosphamide therapy in nine patients with active systemic lupus erythematosus and severe central nervous system involvement. Seven patients had focal neurological deficits and/or seizures associated with abnormalities on cerebrospinal fluid analysis and/or magnetic resonance imaging. Two patients had organic brain syndrome with psychosis and normal cerebrospinal fluid and/or magnetic resonance imaging analysis. Six patients were unresponsive to treatment with high dose corticosteroid. Cyclophosphamide, 0.75-1.0 g/m2 body surface area, was administered intravenously every month for at least 2 months. Eight patients had a complete recovery or recovered with minor residuals. Cyclophosphamide was well tolerated with few side effects. We conclude that parenteral pulse cyclophosphamide is an effective adjunctive therapy for the management of patients with active systemic lupus erythematosus and central nervous system symptoms.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1808642     DOI: 10.1093/qjmed/81.3.975

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  21 in total

1.  Neuropsychiatric Symptoms in Lupus.

Authors:  Maria Gulinello; Jing Wen; Chaim Putterman
Journal:  Psychiatr Ann       Date:  2012-09

Review 2.  Systemic lupus erythematosus--disease management.

Authors:  M F Gourley
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus.

Authors:  L Barile-Fabris; R Ariza-Andraca; L Olguín-Ortega; L J Jara; A Fraga-Mouret; J M Miranda-Limón; J Fuentes de la Mata; P Clark; F Vargas; J Alocer-Varela
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

4.  Behavioral heterogeneity in an animal model of neuropsychiatric lupus.

Authors:  Boris Sakic; Steven E Hanna; Jason M Millward
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

Review 5.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

Review 6.  Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus.

Authors:  Samir D Bhangle; Neil Kramer; Elliot D Rosenstein
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

7.  Markers of acute neuropsychiatric systemic lupus erythematosus: a multidisciplinary evaluation.

Authors:  Essam A Abda; Zahraa I Selim; Moustafa E M Radwan; Nagham M Mahmoud; Omar M Herdan; Khalid A Mohamad; Sherifa A Hamed
Journal:  Rheumatol Int       Date:  2012-10-12       Impact factor: 2.631

8.  Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus.

Authors:  Mohamed O Olfat; Sulaiman M Al-Mayouf; Mohamed A Muzaffer
Journal:  Clin Rheumatol       Date:  2004-07-23       Impact factor: 2.980

Review 9.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

10.  Hippocampal damage in mouse and human forms of systemic autoimmune disease.

Authors:  David A Ballok; John Woulfe; Monalisa Sur; Michael Cyr; Boris Sakic
Journal:  Hippocampus       Date:  2004       Impact factor: 3.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.